ストックスクリーナーアプリを入手
2.88
1.41%
0.04
アフターアワーズ：
2.88
OncoCyte Corporation (OCX) 最新ニュース
Oncocyte appoints new independent accounting firm - Investing.com
Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer - The Globe and Mail
BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias - MarketScreener
OncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com - Defense World
OncoCyte Co. (NASDAQ:OCX) Sees Large Increase in Short Interest - Defense World
Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference - TradingView
Oncocyte Unveils Game-Changing Transplant Diagnostic Technology at Major Healthcare Conference - Stock Titan
Analysts’ Recent Ratings Updates for OncoCyte (OCX) - Defense World
Oncocyte Files Secondary Stock Shelf - MarketScreener
OncoCyte (NASDAQ:OCX) Now Covered by Lake Street Capital - Armenian Reporter
Lake Street Capital Initiates Coverage on OncoCyte (NASDAQ:OCX) - Defense World
Lake Street starts OncoCyte coverage with Buy, $5 target By Investing.com - Investing.com Canada
OncoCyte a new buy at Lake Street on transplant rejection testing - MSN
OncoCyte’s Strategic Positioning and Growth Potential in Transplant Rejection Testing - TipRanks
OncoCyte initiated with a Buy at Lake Street - TipRanks
Lake Street Initiates Coverage on OncoCyte (OCX) with Buy Rating - GuruFocus
Lake Street starts OncoCyte coverage with Buy, $5 target - Investing.com India
OncoCyte (NASDAQ:OCX) Receives “Equal Weight” Rating from Stephens - Defense World
OncoCyte (NASDAQ:OCX) Given Buy Rating at Needham & Company LLC - Defense World
OncoCyte Corp’s Positive Earnings Call Highlights Growth - TipRanks
OncoCyte Corp (OCX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Regulatory ... - Yahoo
Earnings call transcript: OncoCyte’s Q4 2024 revenue grows, strategic advances - Investing.com Australia
Needham maintains Buy on OncoCyte, steady $4.25 target - Investing.com India
OncoCyte Corporation (NASDAQ:OCX) Q4 2024 Earnings Call Transcript - Insider Monkey
Needham maintains Buy on OncoCyte, steady $4.25 target By Investing.com - Investing.com South Africa
Positive Outlook on OncoCyte’s Stock Due to Strategic Launch and Financial Management - TipRanks
OncoCyte: Q4 Earnings Snapshot - CT Insider
Oncocyte Corp Reports 2024 Success and 2025 Growth Plans - TipRanks
OncoCyte Corp Q4 2024 Earnings: Revenue Surges to $1.5 Million, Beating Estimates; EPS at -0.43 - GuruFocus
Oncocyte reports progress in organ transplant diagnostics By Investing.com - Investing.com South Africa
Oncocyte targets $20M in recurring revenue from 20 transplant centers by 2025 - MSN
Earnings call transcript: OncoCyte’s Q4 2024 revenue grows, strategic advances By Investing.com - Investing.com South Africa
OncoCyte Corporation (OCX) Q4 Sales Increase - Nasdaq
Oncocyte reports progress in organ transplant diagnostics - Investing.com India
OncoCyte: Q4 Earnings Snapshot -March 24, 2025 at 04:29 pm EDT - Marketscreener.com
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts - GlobeNewswire
Oncocyte secures $29.1 million to advance FDA assay - MSN
OncoCyte Corp expected to post a loss of 43 cents a shareEarnings Preview - TradingView
Oncocyte Corp Files For Common Stock Offering Of Up To $25.0 MlnSEC Filing - Reuters
Oncocyte corp investor Patrick Smith buys $1,839 in shares - MSN
Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025 - The Manila Times
OncoCyte Corporation (OCX): Among Top Insider Purchases Last Month - MSN
OncoCyte Announces Executive Promotions and Compensation Changes - TipRanks
0.15%
4.32%
大文字化:
|
ボリューム (24 時間):